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Pneumolysin (PLY), an important virulence factor of Streptococcus pneumoniae, is known to exert various
effects on the host immune cells, including cytokine induction, in addition to its known cytolytic activity as a
member of the thiol-activated cytolysins. It is of interest to determine whether cytolytic activity is involved in
triggering the cytokine production. In this study, we constructed full-length recombinant PLY and noncytolytic
truncated PLYs with C-terminal deletions to examine the response of spleen cells to these PLY preparations.
When cytolytic activity was blocked by treatment with cholesterol, full-length PLY was capable of inducing
gamma interferon (IFN-) production. Truncated PLYs that originally exhibited no cytolytic activity were also
active in IFN- induction. Therefore, the IFN--inducing ability of PLY appeared to be independent of the
cytolytic activity. Furthermore, IFN--inducing preparations were also capable of inducing nitric oxide syn-
thase expression and nitric oxide (NO) production, and the addition of neutralizing antibody to IFN-
abolished the NO production. These results clearly demonstrated that PLY is capable of inducing IFN-
production in spleen cells by a mechanism different from pore formation and that the induced IFN-
stimulates NO production. These findings were discussed with reference to the contribution of PLY to the
virulence of S. pneumoniae in vivo.
Streptococcus pneumoniae is an important human pathogen
that causes life-threatening diseases such as pneumonia and
meningitis, as well as less serious but very prevalent diseases
such as otitis media and sinusitis. Interest has been focused on
the virulence mechanism of this bacterium because of the
numerous number of deaths associated with pneumococcal
disease (13, 21), the emergence of antibiotic resistance (16, 29,
38, 44), and the problems in efficacy of current vaccines, espe-
cially for children younger than 2 years of age and immuno-
compromised patients (2, 13, 18, 21, 30).
Pneumolysin (PLY), produced by all clinical isolates of S.
pneumoniae, is a 53-kDa protein toxin consisting of 471 amino
acids (43). PLY has been regarded as an essential virulence
factor of this bacterium (1, 7–10, 34, 35) and one of the can-
didates for vaccine development against pneumococcal infec-
tion (2, 25, 31). PLY is a pore-forming, cytolytic toxin and a
member of the family of structurally related thiol-activated
cytolysins (TACYs), including listeriolysin O (LLO), streptol-
ysin O (SLO), and perfringolysin O (PFO), with a common
characteristic that the cytolytic activity is abrogated by choles-
terol and is dependent on the presence of highly conserved
undecapeptide at the C termini (3, 11). In addition to the
direct damage of host cells, PLY has been reported to affect
various host responses. At sublytic concentrations, several
studies have indicated the inhibition by PLY of respiratory
burst in human phagocytes (27, 32) and lymphokine produc-
tion (17), which were blocked by treatment with cholesterol.
PLY is also shown to activate phospholipase A in endothelial
cells of the pulmonary artery through the pore-forming mech-
anism (36). Recent studies have shown that PLY potentiates
the proinflammatory activity of neutrophils by a pore-forming
mechanism resulting in Ca2 influx (14, 15).
In contrast, there are an accumulating number of reports
showing that PLY is capable of stimulating host response,
including complement activation (26, 33), cytokine production
from human monocytes (20), and nitric oxide (NO) production
from murine macrophages (12). Thus, PLY appears to exhibit
dual aspects of biological activity; however, little is known
about the relationship between cytolytic and stimulating activ-
ities.
Among family members of the TACYs, SLO (19, 37) and
LLO (23, 40) have been reported to exert various effects on
host cells leading to the modulation of inflammatory response.
We have previously reported that LLO from Listeria monocy-
togenes is a potent inducer for cytokines in spleen cells (28).
Among various cytokines induced by LLO, a striking level of
gamma interferon (IFN-) production was observed, and we
have shown that IFN- plays an important role especially for
inducing protective immunity to L. monocytogenes (45). Induc-
tion of protective TH1 cells could be achieved by immunization
of mice with an LLO-negative strain of L. monocytogenes,
along with liposome-encapsulated LLO (41). In addition, we
have also shown that the IFN--inducing ability of LLO was
not affected by cholesterol treatment, although the hemolytic
activity of LLO was blocked (28). It was suggested that LLO
could induce IFN- production in spleen cells by a mechanism
different from cytolytic activity.
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Based on the findings described above, there was a possibil-
ity that PLY exerts IFN--inducing ability even in the absence
of cytolytic activity like that of LLO. In the present study, we
have constructed a full-length PLY and two C-terminal trun-
cated forms of PLY to determine whether PLY is capable of
inducing IFN- independent of pore-forming activity. By using
recombinant PLY preparations, we have examined the ability
to induce IFN- production and NO production that highly
depends on the IFN- produced.
MATERIALS AND METHODS
Bacterial strains, plasmids, and media. S. pneumoniae IID553 (serotype 2),
one of the standard strains of the Japanese Society for Bacteriology, was ob-
tained from the Laboratory Culture Collection (Institute of Medical Science,
University of Tokyo, Tokyo, Japan) and grown in brain heart infusion broth
(Difco Laboratories, Detroit, Mich.) at 37°C for preparation of chromosomal
DNA. Escherichia coli M15 (Qiagen, Hilden, Germany) harboring pREP4 plas-
mid, which contains lacI and kanamycin-resistant genes, was used as a host cell.
Expression vector pQE-31 (Qiagen), which is designed to place a tag of six
histidines (His6) at the N terminus of the protein of interest, was used. In order
to express the recombinant protein, E. coli harboring recombinant plasmid was
grown in tryptic soy broth (Difco) containing 100 g of ampicillin and 25 g of
kanamycin/ml.
Production and purification of recombinant PLYs. The full-length form of
PLY, PLY471, consisting of 471 amino acids, and two truncated forms of PLY,
PLY437 and PLY426, with deletion of C-terminal 34 and 45 amino acids includ-
ing undecapeptide, respectively, were prepared by the procedure described pre-
viously (4). Briefly, chromosomal DNA extracted from S. pneumoniae IID553
was used as a template in PCR. The gene encoding full-length or truncated PLYs
was amplified by PCR with the specific primer sets designed according to the
sequence of the ply gene (43). The primers contained modifications to add
appropriate restriction enzyme sites for insertion into the vector: a BamHI site
in the forward primer and a KpnI site in the reverse primer. The sequences of all
PCR products were confirmed by DNA sequencing with an ABI PRISM310
Genetic Analyzer (PE Applied Biosystems, Foster City, Calif.). Both PCR prod-
uct and pQE-31 expression vector were cut with BamHI and KpnI enzymes (New
England Biolabs, Beverly, Mass.) and ligated by using T4 ligase (New England
Biolabs). The recombinant plasmid was transformed into E. coli M15 by elec-
troporation by using the Gene Pulser II Electroporation System (Bio-Rad Lab-
oratories, Hercules, Calif.). Transformants were cultured in tryptic soy broth
(Difco) containing ampicillin and kanamycin, and isopropyl--D-thiogalactopyr-
anoside (IPTG) was added to induce the expression of His-tagged recombinant
protein at the middle of the log phase of the culture. The cells were harvested by
centrifugation at 4°C after an appropriate period of the induction, resuspended
in phosphate buffer (50 mM Na2HPO4, pH 8.0; 300 mM NaCl) containing 20
mM imidazole, and disrupted by homogenization with zirconia-silica beads (Bio-
Spec Products, Inc., Bartlesville, Okla.) after treatment with 1 mg of lysozyme/ml
on ice. Lysate was centrifuged at 10,000  g for 30 min at 4°C. His-tagged
recombinant protein was purified from the supernatant with an Ni-nitrilotriacetic
acid (NTA) column (Qiagen) under native conditions according to the manu-
facturer’s instructions. Purified recombinant protein was desalted by a passage
through a PD-10 column of Sephadex G-25 M (Amersham Pharmacia Biotech,
Buckinghamshire, United Kingdom). Contaminating lipopolysaccharide (LPS)
was extensively removed by using Detoxi-Gel Endotoxin Removing Gel (Pierce
Chemical Company, Rockford, Ill.). The level of LPS was determined by Limulus
Color KY Test (Wako Pure Chemical Industries, Osaka, Japan). The purity was
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and im-
munoblotting by using anti-His-tag monoclonal antibody (Penta-His Antibody;
Qiagen).
Cell culture. C3H/HeN mice (SLC Japan, Hamamatsu, Japan) were used for
experiments at 7 to 9 weeks of age. Normal spleen cells were aseptically removed
from mice and teased between two sterile glass slides. After erythrocytes were
lysed by treatment with 0.83% ammonium chloride in 0.17 mM Tris-HCl (pH
7.6), spleen cells were washed three times with Hanks balanced salt solution and
suspended in RPMI 1640 medium (Gibco-BRL/Life Technologies, Inc., Rock-
ville, Md.) supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum
(Gibco) and 5 g of gentamicin/ml. The cells were plated at 2.5  106 per well
in a 48-well flat-bottomed tissue culture plate and stimulated with various con-
centrations of recombinant PLYs at 37°C in 5% CO2 for 24 or 48 h. The culture
supernatant was collected by centrifugation for the measurement of the level of
IFN- or NO produced from spleen cells. To determine the participation of
IFN- in NO production, spleen cells were stimulated with recombinant PLYs in
the presence of 2 g of rat anti-mouse IFN- monoclonal antibody (R&D
Systems, Inc., Minneapolis, Minn.)/ml for 48 h, and NO production from spleen
cells was measured.
IFN- and NO assay. The IFN- level was measured by enzyme immunoassay
(EIA) as follows. The wells of an EIA plate (Nalge Nunc International, Roch-
ester, N.Y.) were precoated with rat anti-mouse IFN- antibody (Endogen, Inc.,
Woburn, Mass.) diluted at 1 g/ml with coating buffer (0.03 M sodium carbonate,
0.068 M sodium bicarbonate; pH 9.6). After incubation overnight at 4°C, the
plate was washed with distilled water and then treated with 25% Block Ace
(Dainippon Pharmaceutical Co., Ltd., Osaka, Japan) for 60 min to inhibit non-
specific binding. After a wash with phosphate-buffered saline (PBS) containing
0.1% Tween 20 (PBS-Tween), 50 l of the test supernatants or standard murine
IFN- was added to each well. After incubation for 60 min at room temperature,
50 l of 0.5 g of biotin-conjugated anti-mouse IFN- monoclonal antibody
(Endogen)/ml was added to each well without washing, and the plate was incu-
bated further for 60 min. After a wash with PBS-Tween, 0.125 g of horseradish
peroxidase-conjugated streptavidin (Endogen)/ml was added. After incubation
for 30 min, wells were washed, and then 100 l of 3,3,5,5-tetramethylbenzidine
dihydrochloride dihydrate (TMB) (50 g/ml) in phosphate-citrate buffer (pH
5.0) containing 0.01% H2O2 was added as a substrate solution. The absorbance
was measured at 450 nm after termination of the reaction with 100 l of 0.18 M
H2SO4. For quantification of NO production, the concentration of nitrite in the
culture supernatant was measured by Griess reaction by using modified Griess
reagent (Sigma-Aldrich, Inc., St. Louis, Mo.). A total of 100 l of Griess reagent
was mixed with an equal volume of the test supernatant or standard in a 96-well
flat-bottom plate. After incubation at room temperature for 15 min, the absor-
bance was measured at 540 nm. Nitrite was quantitated with sodium nitrite as a
standard.
Cytotoxicity assay. The cytotoxic activity of recombinant PLYs for spleen cells
was determined by measuring the level of lactate dehydrogenase (LDH) in
culture supernatant released from spleen cells. Cells were plated at 2.5  106 per
well in a 48-well flat-bottom tissue culture plate and incubated in the presence of
various doses of recombinant PLYs for 6 h. The culture supernatant was col-
lected, and the level of LDH was measured by using an LDH Cytotoxicity
Detection Kit (Takara Shuzo Co., Ltd., Otsu, Japan) according to the manufac-
turer’s instructions. Samples treated with 1% Triton X-100 or those with culture
medium alone were defined as positive (100% LDH release) and negative (0%
LDH release) controls, respectively, and then the relative LDH release (%) for
each well was calculated.
RT-PCR. Spleen cells were plated at 5.0 106 per well in a 24-well flat-bottom
tissue culture plate and stimulated with recombinant PLYs at 37°C in 5% CO2
for 12 h. Total cellular RNA was extracted by RNeasy Mini Kit (Qiagen) ac-
cording to the manufacturer’s instructions, and then cDNA was produced by
reverse transcription (RT) as follows. The total RNA extracted (100 ng) was
mixed with 10 l of 5 RT buffer, 5 l of 100 mM dithiothreitol, 1.25 l of
RNasin (Promega, Madison, Wis.), 2.5 l of 10 mM deoxynucleoside triphos-
phates (dNTPs; Amersham), 1.75 l of random primer (Gibco), 1.25 l of
reverse transcriptase (SuperScript II RNase H Reverse Transcriptase; Gibco),
and distilled water to give a total volume of 50 l. The RT reaction was carried
out by four steps consisting of 42°C for 1 min, 30°C for 10 min, 42°C for 25 min,
and 94°C for 3 min for inactivation. The samples were kept at 20°C until used.
The PCR mixture consisted of 2 l of sample cDNA, 2 l of 10 PCR buffer,
and 0.8 l of 25 mM Mg2SO4, 2 l of 2 mM dNTPs, 0.3 l of 20 M forward
primer, 0.3 l of 20 M reverse primer, 0.4 l of DNA polymerase (KOD-Plus;
Toyobo, Osaka, Japan), and distilled water to give a total volume of 20 l. The
sequences of the oligonucleotide primers used were as follows: 5-CCCTTCCG
AAGTTTCTGGCAGCAGC-3 and 5-GGCTGTCAGAGCCTCGTGGCTTT
GG-3 for inducible nitric oxide synthase (iNOS) and 5-TGGAATCCTGTG
GCATCCATGAAAC-3 and 5-TAAAACGCAGCTCAGTAACAGTCCG-3
for -actin. The predicted sizes of the amplified products for iNOS and -actin
were 497 and 349 bp, respectively. PCR amplification was performed by a
thermal cycler (GeneAmp PCR System 9700; PE Applied Biosystems). The PCR
program consisted of one cycle of 94°C for 15 s, 55°C for 30 s, and 68°C for 60 s.
Samples were amplified for 31 cycles for iNOS and 23 cycles for -actin, followed
by incubation at 68°C for 7 min, and the products were kept at 4°C in the cycler.
Analysis of the PCR products was performed by agarose gel electrophoresis with
a 2% low-melting-point agarose gel in 0.5 Tris-acetate-EDTA buffer. PCR
products were electrophoresed on 2% agarose gel and the gel was stained with
0.005% ethidium bromide. The bands were visualized by a UV transilluminator.
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RESULTS
IFN--inducing ability and cytotoxicity of full-length PLY.
Normal spleen cells were stimulated for 24 h with full-length
PLY (PLY471) that had been treated with or without choles-
terol, and then the level of IFN- in the culture supernatant
was assayed by EIA. We also measured the level of LDH in
culture supernatant released from spleen cells to determine
the cytotoxicity. According to the results of preliminary exper-
iments, we determined the LDH release 6 h after the addition
of PLY because the LDH level at this time points represented
the real cytotoxicity without high background due to sponta-
neous release. In the range of 6.25 to 50 nM, full-length
PLY471 exhibited cytotoxicity to spleen cells if not treated with
cholesterol. IFN- production was not induced at all by various
concentrations of cytolytic PLY (Fig. 1). Though there are
several reports showing that the sublytic concentration of PLY
induced inflammatory cytokines from human mononuclear
phagocytes (20) and superoxide, elastase, prostaglandin E2,
and leukotriene B4 from human neutrophils (14, 15), our prep-
aration of PLY471 did not induce IFN- production even at
much lower, sublytic concentrations (data not shown). In con-
trast, when PLY471 was treated with 10 g of cholesterol/ml to
inhibit its cytolytic activity, it became capable of inducing
IFN- production at concentrations of 12.5 and 25 nM, a dose
range that never causes LDH release from the cells. At higher
concentrations, the level of IFN- production became lower
probably because of the incomplete blockade of cytotoxicity
due to the limit in the amount of cholesterol solubilized for
pretreatment (Fig. 1). These data implied that PLY471 could
induce IFN- production by a mechanism different from cyto-
lytic, pore-forming activity, and the cytotoxicity of PLY471
seemed to interfere with IFN--inducing ability.
IFN--inducing ability and cytotoxicity of truncated PLYs.
In our previous report, we constructed truncated PLYs with
the deletions of C-terminal 34 amino acids (PLY437) and 45
amino acids (PLY426), neither of which showed the ability to
bind to membrane cholesterol or hemolytic activity (4). In
order to confirm that PLY is able to induce IFN- production
independently of cytolytic, pore-forming activity, we examined
the IFN--inducing ability of these nonhemolytic recombinant
PLYs with C-terminal truncations. We examined first whether
both of these truncated PLYs had no cytotoxicity against
spleen cells as well as erythrocytes. As shown in Fig. 2, two
truncated recombinant PLYs exhibited no cytotoxicity at all
against spleen cells even at higher concentrations. After con-
firmation of the absence of cytotoxicity, the IFN--inducing
ability of these noncytolytic preparations, PLY437 and
PLY426, was examined. PLY437 was capable of inducing
IFN- production at doses of 200 nM (Fig. 2A), although the
dose required was higher than that for cholesterol-treated
PLY471. PLY426 was also able to induce IFN- production at
a much higher concentration, 800 nM (Fig. 2B). In order to
rule out the possibility that IFN- production depends on
contaminating LPS, recombinant proteins were passed exten-
sively through an LPS-removing column. The amount of LPS
in the working concentration of PLY preparations was less
than 10 pg/ml. As shown in Fig. 3, IFN- production was not
induced in the spleen cells by 10 pg of exogenously added
LPS/ml. In addition, the IFN--inducing ability of recombinant
PLYs was not affected by polymyxin B, whereas the response to
1 ng of LPS/ml was completely inhibited by the same treat-
ment, indicating that the possible involvement of LPS could be
ruled out. These results indicated that IFN--inducing ability
of recombinant PLY was not associated with cytolytic, pore-
forming activity and not due to the contaminating LPS.
Expression of iNOS in spleen cells stimulated with recom-
binant PLYs. IFN- is highly capable of inducing iNOS expres-
sion and NO production in macrophages (22) and spleen cells
(46). There is a report showing that PLY induced iNOS ex-
pression and NO production in murine macrophages through a
pathway dependent on IFN- signaling (12). Based on these
reports, we examined the induction of iNOS by the recombi-
nant PLYs that showed IFN--inducing ability but no pore-
forming activity. Normal spleen cells were stimulated with cho-
lesterol-treated PLY471 (25 nM), PLY437 (400 nM), and
PLY426 (800 nM) at the concentrations effective for inducing
IFN- production. After 24 h of stimulation, total RNA was
extracted from the cells and subjected to RT-PCR for ampli-
fication of iNOS mRNA. A significant level of iNOS expression
was observed in the spleen cells after stimulation with all three
recombinant preparations (Fig. 4).
NO production by spleen cells stimulated with recombinant
PLYs. We next measured the actual production of NO in the
culture supernatant of spleen cells. Spleen cells were stimu-
lated with the same preparations used for RT-PCR for 48 h
and then the level of nitrite, the end product of NO, was
FIG. 1. IFN--inducing ability and cytotoxicity of full-length PLY
with or without cholesterol treatment. To determine IFN--inducing
ability, normal spleen cells were stimulated for 24 h with PLY471
(full-length PLY) that had been treated with or without 10 g of
cholesterol/ml and the level of IFN- in the culture supernatant was
assayed by EIA. To determine cytotoxicity for spleen cells, cells were
incubated with the same PLY471 preparations for 6 h, and the level of
LDH released in the culture supernatant from the cells was measured.
Each column represents the level of IFN- induced by PLY471 with
(open column) or without (closed column) cholesterol, and each point
connected by a line represents the cytotoxicity of cholesterol-treated
(open squares) or nontreated (closed circles) PLY471. Data are shown
as the mean of triplicate determinations 	 the standard deviation
(SD). The result shown here is the representative of three similar
experiments.
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assayed by Griess reaction. As shown in Fig. 5, nitrite produc-
tion was observed in the culture after stimulation with recom-
binant PLY preparations that could induce IFN- production.
NO production was not observed at all by stimulation with 0.01
to 50 nM of PLY471 when not pretreated with cholesterol
(data not shown). The amount of nitrite production appeared
to depend on the level of IFN- induced. To determine the
involvement of PLY-induced IFN- in NO production, the
effect of neutralization of IFN- was examined. PLY-induced
nitrite production was inhibited significantly by the addition of
anti-mouse IFN- antibody to the cell culture (Fig. 5). These
results showed that PLY was capable of inducing NO produc-
tion by means of the induced IFN-.
DISCUSSION
PLY has been proved to be an important virulence factor of
S. pneumoniae from in vivo experiments with isogenic mutant
strains of the ply gene (1, 6–10, 34, 35). The cytolytic activity
and complement-activating ability of PLY are believed to con-
tribute to virulence especially in the early stage of infection (1,
6–8, 34). However, several studies suggested the involvement
of some properties of PLY other than cytolytic and comple-
ment-activating activities in virulence (1, 6, 8).
In the present study, we showed that PLY471, a full-length
form of recombinant PLY, was capable of inducing IFN-
production in spleen cells when it was treated with cholesterol
for the abolishment of pore-forming activity (Fig. 1). However,
at the concentration of 25 nM, at which cytotoxicity was not
completely blocked by cholesterol due to the limit in the sol-
ubility of cholesterol, the level of IFN- production became
lower and the IFN--inducing ability was not observed at all in
the cytotoxic PLY471 without cholesterol treatment. These
results implied that the IFN--inducing mechanism was differ-
ent from that in the pore formation and that the cytotoxicity of
PLY471 seemed to interfere with the IFN--inducing ability.
A much higher level of IFN- production was induced by
PLY437 and PLY426, truncated forms of PLY that were con-
firmed to have neither cholesterol-binding nor pore-forming
activity against not only erythrocytes (4) but also spleen cells
(Fig. 2), although a higher concentration was needed than for
PLY471 (Fig. 2). From these results, it can be concluded that
IFN--inducing ability was independent of cholesterol-binding
and pore-forming activities.
The reason is not clear why the higher concentration was
required to induce IFN- in truncated PLYs. In a study of
recombinant PFO, it was reported that C-terminal truncation
caused a disruptive change of overall molecular structure (39).
Therefore, it is plausible that truncation of PLY affected the
molecular structure effective for IFN- induction in addition to
abolishment of cytolytic activity. In comparing two truncated
recombinants, a higher dose of PLY426 was required than of
PLY437 for optimal IFN- induction. If we take into consid-
eration that PLY426 is shorter than PLY437 by 11 amino acids,
it is likely that the molecular structure is critically involved in
the IFN- induction. In any case, the structural requirement
for cytokine induction should be determined in detail.
We sought to rule out the possible involvement of LPS
contamination in the E. coli-derived samples. In the working
concentrations of PLY, the amount of contaminating LPS de-
termined by Limulus assay never exceeded 10 pg/ml, and
IFN- production was not induced in the spleen cells by addi-
tion of 10 pg of LPS derived from E. coli/ml (Fig. 3). In
addition, treatment of our preparations with 0.5 g of poly-
myxin B/ml never affected the activity, whereas the response to
FIG. 2. IFN--inducing ability and cytotoxicity of truncated PLYs with C-terminal deletions. Normal spleen cells were stimulated with PLY437
(A) and PLY426 (B). The levels of IFN- (column) and LDH release (points connected by a line) in the culture supernatant were measured after
24 and 6 h, respectively. Data are shown as the mean of triplicate determinations 	 the SD. The result shown here is the representative of three
similar experiments.
110 BABA ET AL. INFECT. IMMUN.
 o
n
 O
ctober 18, 2015 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
LPS was completely inhibited by the same treatment (Fig. 3).
From these observations, the results presented here can be
regarded as the activity of recombinant protein itself and not
an artifact by contaminating LPS.
We could also observe iNOS gene expression (Fig. 4) and
NO production (Fig. 5) in the spleen cells stimulated with the
PLY preparations that showed IFN--inducing ability. NO
production was not seen in the condition where no IFN- was
induced. In addition, the NO production induced by IFN--
inducing PLY preparations was inhibited by the addition of
anti-mouse IFN- antibody (Fig. 5). These results indicated
that PLY was capable of inducing NO production through the
induction of IFN- production.
IFN- has been reported to induce iNOS expression and NO
production in macrophages (22) and spleen cells (46). Re-
cently, Braun et al. reported that PLY could induce NO pro-
duction from murine macrophages at a range of 5 to 750 nM
and suggested that the NO production depended on the IFN-
signaling pathway by using mice lacking IFN- receptor or IFN
regulatory factor 1 (12). Their findings are consistent with our
present results showing that a high level of IFN- production
was actually induced by PLY, resulting in NO production. In
their report, however, nothing was mentioned about the dis-
sociation between cytolytic activity and NO-inducing ability.
The most important finding in our study is that even trun-
cated PLY without cytolytic activity was capable of inducing
NO production. NO seems now to contribute to septic shock
caused by gram-positive bacteria resulting in hypotension, vas-
cular hyporeactivity to vasoconstrictors, and multiple organ
failure (24, 42). There are reports on the virulence of an S.
pneumoniae mutant in which various point mutations were
introduced in the ply gene (1, 6–8, 34). In these reports, it was
suggested that PLY must have additional properties for viru-
lence expression that were not abolished by the point muta-
tions abrogating cytolytic activity (1, 6, 8). Our finding of the
IFN--inducing, NO-inducing activity of noncytolytic trun-
cated PLY may explain their findings regarding the dissocia-
tion between cytolytic activity and virulence expression in vivo.
Although NO was not measured, Benton et al. reported that
IFN- was detected in the plasma from mice infected with S.
pneumoniae at a septic state just prior to death but not in mice
infected with the ply-negative mutant strain (5). Therefore,
there is a possibility that the IFN-- and NO-inducing abilities
of PLY presented here may contribute to the virulence of S.
pneumoniae in the late stage near death in which a large num-
ber of this bacteria exist in circulating blood.
In conclusion, we demonstrated clearly that PLY is capable
of inducing IFN- production in spleen cells by a mechanism
FIG. 3. Effect of polymyxin B (PMB) on IFN- production induced
by recombinant PLYs. Normal spleen cells were stimulated with re-
combinant PLYs or LPS for 24 h in the presence (open column) or
absence (closed column) of 5 g of polymyxin B/ml. The culture
supernatant was collected, and the IFN- was measured by EIA. Data
are shown as the mean of triplicate determinations 	 the SD. The
same experiment was repeated twice, and a similar result was obtained.
FIG. 4. Expression of iNOS mRNA in the spleen cells stimulated with recombinant PLYs. Normal spleen cells were stimulated for 24 h with
PLY471 (25 nM), PLY437 (400 nM), or PLY426 (800 nM), at the concentration optimal for IFN- induction for each recombinant protein. Total
RNA was extracted and subjected to RT-PCR. PCR products obtained by using specific primer sets for iNOS and -actin were electrophoresed.
The predicted sizes of PCR products for iNOS and -actin are indicated. Bands in the left lane indicate the positions of DNA size markers. The
same experiment was repeated twice, and a similar result was obtained.
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different from pore formation and that the induced IFN-
leads to NO production that might contribute to the virulence
of S. pneumoniae in a septic state.
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